AZD6750 + rilvegostomig

**AZD6750 + rilvegostomig** is an investigational combination therapy in early-phase clinical trials for advanced or metastatic solid tumors. - **AZD6750** is a CD8-guided interleukin-2 (IL-2) therapeutic agent designed to enhance T-cell mediated anti-tumor immunity by selectively activating and expanding cytotoxic CD8+ T cells, potentially minimizing activation of regulatory T cells and reducing systemic toxicity. - **Rilvegostomig** (also known as AZD2936) is a bispecific monoclonal antibody that simultaneously targets PD-1 and TIGIT, two immune checkpoint receptors. By blocking both, rilvegostomig aims to reinvigorate exhausted T cells and augment immune responses against cancer. The combination is being evaluated primarily in adults with non-small cell lung cancer (NSCLC), especially those with PD-L1 expression ≥1%, and in select other tumors where immune checkpoint inhibitors have activity. Both agents are administered intravenously.

Other names

AZD2936AZD-2936AZD 2936